Fulton Bank N.A. Acquires 6,535 Shares of Sanofi (NASDAQ:SNY)

Fulton Bank N.A. boosted its position in Sanofi (NASDAQ:SNY - Free Report) by 13.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,538 shares of the company's stock after purchasing an additional 6,535 shares during the period. Fulton Bank N.A.'s holdings in Sanofi were worth $3,080,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. McClarren Financial Advisors Inc. boosted its holdings in Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after acquiring an additional 543 shares during the last quarter. Lee Danner & Bass Inc. purchased a new stake in shares of Sanofi during the fourth quarter worth about $31,000. Bessemer Group Inc. increased its position in shares of Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after acquiring an additional 242 shares during the last quarter. Sierra Ocean LLC purchased a new stake in shares of Sanofi during the fourth quarter worth about $44,000. Finally, Whipplewood Advisors LLC purchased a new stake in shares of Sanofi during the fourth quarter worth about $76,000. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Trading Up 0.6%

SNY traded up $0.31 during trading on Wednesday, reaching $49.50. 1,392,171 shares of the company's stock were exchanged, compared to its average volume of 2,404,158. The company's fifty day moving average price is $52.03 and its 200-day moving average price is $51.94. The firm has a market capitalization of $121.40 billion, a PE ratio of 19.88, a P/E/G ratio of 1.01 and a beta of 0.55. Sanofi has a fifty-two week low of $45.80 and a fifty-two week high of $60.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The firm had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same quarter in the prior year, the business posted $1.78 EPS. The business's revenue was down 11.0% compared to the same quarter last year. As a group, equities analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be paid a $2.0369 dividend. This is an increase from Sanofi's previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. This represents a yield of 3.1%. Sanofi's dividend payout ratio is presently 57.14%.

Wall Street Analyst Weigh In

Several research firms have recently commented on SNY. BNP Paribas began coverage on Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 target price for the company. The Goldman Sachs Group started coverage on Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price for the company. Finally, Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Sanofi currently has a consensus rating of "Buy" and a consensus target price of $63.33.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.